228 related articles for article (PubMed ID: 35906755)
41. Shortened-Duration Immunosuppressive Therapy after Nonmyeloablative, Related HLA-Haploidentical or Unrelated Peripheral Blood Grafts and Post-Transplantation Cyclophosphamide.
DeZern AE; Elmariah H; Zahurak M; Rosner GL; Gladstone DE; Ali SA; Huff CA; Swinnen LJ; Imus P; Borrello I; Wagner-Johnston ND; Ambinder RF; Brodsky RA; Cooke K; Luznik L; Fuchs EJ; Bolaños-Meade J; Jones RJ
Biol Blood Marrow Transplant; 2020 Nov; 26(11):2075-2081. PubMed ID: 32818556
[TBL] [Abstract][Full Text] [Related]
42. HLA-Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplant Cyclophosphamide after Busulfan-Containing Reduced-Intensity Conditioning.
Sugita J; Kawashima N; Fujisaki T; Kakihana K; Ota S; Matsuo K; Miyamoto T; Akashi K; Taniguchi S; Harada M; Teshima T;
Biol Blood Marrow Transplant; 2015 Sep; 21(9):1646-52. PubMed ID: 26093044
[TBL] [Abstract][Full Text] [Related]
43. Elafin as a Predictive Biomarker of Acute Skin Graft-
Solán L; Carbonell D; Muñiz P; Dorado N; Landete E; Chicano-Lavilla M; Anguita J; Gayoso J; Kwon M; Díez-Martín JL; Martínez-Laperche C; Buño I
Front Immunol; 2021; 12():516078. PubMed ID: 33679728
[TBL] [Abstract][Full Text] [Related]
44. Current status of conditioning regimens in haploidentical hematopoietic cell transplantation.
Sugita J; Yanada M
Hematology; 2024 Dec; 29(1):2332866. PubMed ID: 38511645
[TBL] [Abstract][Full Text] [Related]
45. Posttransplantation Cyclophosphamide- and Sirolimus-Based Graft-Versus-Host-Disease Prophylaxis in Allogeneic Stem Cell Transplant.
Greco R; Lorentino F; Albanese S; Lupo Stanghellini MT; Giglio F; Piemontese S; Clerici D; Lazzari L; Marcatti M; Mastaglio S; Xue E; Farina F; Pavesi F; Assanelli A; Carrabba MG; Marktel S; Vago L; Bonini C; Corti C; Bernardi M; Ciceri F; Peccatori J
Transplant Cell Ther; 2021 Sep; 27(9):776.e1-776.e13. PubMed ID: 34087452
[TBL] [Abstract][Full Text] [Related]
46. Feasibility of HLA-haploidentical hematopoietic stem cell transplantation with post-transplantation cyclophosphamide for advanced pediatric malignancies.
Sawada A; Shimizu M; Isaka K; Higuchi K; Mayumi A; Yoshimoto Y; Kikuchi H; Kondo O; Koyama-Sato M; Yasui M; Kawa K; Inoue M
Pediatr Hematol Oncol; 2014 Nov; 31(8):754-64. PubMed ID: 25325678
[TBL] [Abstract][Full Text] [Related]
47. [Allogeneic hematopoietic stem cell transplantation using posttransplant cyclophosphamide].
Sugita J
Rinsho Ketsueki; 2020; 61(9):1402-1410. PubMed ID: 33162542
[TBL] [Abstract][Full Text] [Related]
48. Prospective Randomized Study Comparing Myeloablative Unrelated Umbilical Cord Blood Transplantation versus HLA-Haploidentical Related Stem Cell Transplantation for Adults with Hematologic Malignancies.
Sanz J; Montoro J; Solano C; Valcárcel D; Sampol A; Ferrá C; Parody R; Lorenzo I; Montesinos P; Ortí G; Hernández-Boluda JC; Balaguer-Roselló A; Guerreiro M; Carretero C; Sanz GF; Sanz MA; Piñana JL
Biol Blood Marrow Transplant; 2020 Feb; 26(2):358-366. PubMed ID: 31655119
[TBL] [Abstract][Full Text] [Related]
49. A Two-Step Haploidentical Versus a Two-Step Matched Related Allogeneic Myeloablative Peripheral Blood Stem Cell Transplantation.
Gaballa S; Palmisiano N; Alpdogan O; Carabasi M; Filicko-O'Hara J; Kasner M; Kraft WK; Leiby B; Martinez-Outschoorn U; O'Hara W; Pro B; Rudolph S; Sharma M; Wagner JL; Weiss M; Flomenberg N; Grosso D
Biol Blood Marrow Transplant; 2016 Jan; 22(1):141-8. PubMed ID: 26415558
[TBL] [Abstract][Full Text] [Related]
50. Sequential Transplantation of Haploidentical Stem Cell and Unrelated Cord Blood With Using ATG/PTCY Increases Survival of Relapsed/Refractory Hematologic Malignancies.
Li H; Li X; Chen Y; Li D; Chen X; Zhu Z; Wang Y; Huang J; Chen P; Chen Y; Li N
Front Immunol; 2021; 12():733326. PubMed ID: 34804017
[TBL] [Abstract][Full Text] [Related]
51. Posttransplant cyclophosphamide vs tacrolimus-based GVHD prophylaxis: lower incidence of relapse and chronic GVHD.
Maurer K; Ho VT; Inyang E; Cutler C; Koreth J; Shapiro RM; Gooptu M; Romee R; Nikiforow S; Antin JH; Wu CJ; Ritz J; Soiffer RJ; Kim HT
Blood Adv; 2023 Aug; 7(15):3903-3915. PubMed ID: 37156098
[TBL] [Abstract][Full Text] [Related]
52. Feasibility and Outcome of Haploidentical Hematopoietic Stem Cell Transplantation with Post-Transplant High-Dose Cyclophosphamide for Children and Adolescents with Hematologic Malignancies: An AIEOP-GITMO Retrospective Multicenter Study.
Berger M; Lanino E; Cesaro S; Zecca M; Vassallo E; Faraci M; De Bortoli M; Barat V; Prete A; Fagioli F
Biol Blood Marrow Transplant; 2016 May; 22(5):902-9. PubMed ID: 26860636
[TBL] [Abstract][Full Text] [Related]
53. Thiotepa and antithymocyte globulin-based conditioning prior to haploidentical transplantation with posttransplant cyclophosphamide in high-risk hematological malignancies.
Peric Z; Mohty R; Bastos J; Brissot E; Battipaglia G; Belhocine R; Sestili S; Giannotti F; Vekhoff A; Ledraa T; Legrand O; Lapusan S; Isnard F; Labopin M; Bonnin A; Mediavilla C; Rubio MT; Ruggeri A; Duléry R; Malard F; Mohty M
Bone Marrow Transplant; 2020 Apr; 55(4):763-772. PubMed ID: 31673080
[TBL] [Abstract][Full Text] [Related]
54. Low- versus standard-dose post-transplant cyclophosphamide as GVHD prophylaxis for haploidentical transplantation.
Fuji S; Sugita J; Najima Y; Konishi T; Tanaka T; Ohigashi H; Eto T; Nagafuji K; Hiramoto N; Matsuoka KI; Maruyama Y; Ota S; Ishikawa J; Kawakita T; Akasaka T; Kamimura T; Hino M; Fukuda T; Atsuta Y; Yakushijin K
Br J Haematol; 2024 Mar; 204(3):959-966. PubMed ID: 38037468
[TBL] [Abstract][Full Text] [Related]
55. [HLA-haploidentical peripheral blood stem cell transplantation with post-transplantation cyclophosphamide for adult T-cell leukemia].
Ishii K; Okamoto S; Fujita M; Sugihara A; Nagaie T; Nishioka A; Kamachi K; Itamura H; Katsuya H; Yoshimura M; Ureshino H; Ando T; Kubota Y; Kimura S
Rinsho Ketsueki; 2022; 63(5):333-340. PubMed ID: 35662154
[TBL] [Abstract][Full Text] [Related]
56. Allogeneic Blood or Marrow Transplantation with Post-Transplantation Cyclophosphamide as Graft-versus-Host Disease Prophylaxis in Multiple Myeloma.
Ghosh N; Ye X; Tsai HL; Bolaños-Meade J; Fuchs EJ; Luznik L; Swinnen LJ; Gladstone DE; Ambinder RF; Varadhan R; Shanbhag S; Brodsky RA; Borrello IM; Jones RJ; Matsui W; Huff CA
Biol Blood Marrow Transplant; 2017 Nov; 23(11):1903-1909. PubMed ID: 28711728
[TBL] [Abstract][Full Text] [Related]
57. Thiotepa, Busulfan, and Fludarabine Conditioning Regimen in T Cell-Replete HLA-Haploidentical Hematopoietic Stem Cell Transplantation.
Duléry R; Bastos J; Paviglianiti A; Malard F; Brissot E; Battipaglia G; Médiavilla C; Giannotti F; Banet A; de Wyngaert ZV; Ledraa T; Belhocine R; Sestili S; Adaeva R; Lapusan S; Isnard F; Legrand O; Vekhoff A; Rubio MT; Ruggeri A; Mohty M
Biol Blood Marrow Transplant; 2019 Jul; 25(7):1407-1415. PubMed ID: 30871978
[TBL] [Abstract][Full Text] [Related]
58. Haploidentical transplantation using T cell replete peripheral blood stem cells and myeloablative conditioning in patients with high-risk hematologic malignancies who lack conventional donors is well tolerated and produces excellent relapse-free survival: results of a prospective phase II trial.
Solomon SR; Sizemore CA; Sanacore M; Zhang X; Brown S; Holland HK; Morris LE; Bashey A
Biol Blood Marrow Transplant; 2012 Dec; 18(12):1859-66. PubMed ID: 22863841
[TBL] [Abstract][Full Text] [Related]
59. Pretransplant active disease status and HLA class II mismatching are associated with increased incidence and severity of cytokine release syndrome after haploidentical transplantation with posttransplant cyclophosphamide.
Mariotti J; Taurino D; Marino F; Bramanti S; Sarina B; Morabito L; De Philippis C; Di Vito C; Mavilio D; Carlo-Stella C; Della Porta M; Santoro A; Castagna L
Cancer Med; 2020 Jan; 9(1):52-61. PubMed ID: 31702882
[TBL] [Abstract][Full Text] [Related]
60. Systematic overview of HLA-matched allogeneic hematopoietic cell transplantation with post-transplantation cyclophosphamide.
Nakamae H
Int J Hematol; 2022 Oct; 116(4):465-481. PubMed ID: 35930118
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
